Last updated: February 22, 2026
What Is NDC 00591-0860?
NDC 00591-0860 is an intravenous (IV) formulation of sodium chloride (0.9%) used for fluid replenishment and electrolyte balance. It is a generic, sterile, aqueous solution supplied in vials, primarily prescribed in hospitals, clinics, and long-term care facilities.
Market Size and Demand Drivers
Current Market Scope
- Total U.S. sodium chloride IV solution market estimated at approximately $300 million annually, with steady growth.
- Volume consumption summarized at around 250 million units (vials) annually, based on hospital procurement data (IQVIA, 2022).
- The market reflects high utilization in inpatient settings, with most drugs administered in hospitals or outpatient clinics.
Demand Factors
- Aging population increases chronic disease prevalence (CHF, dehydration, electrolyte imbalance).
- Hospital admissions for dehydration, surgery, and infections sustain demand.
- Suppliers include major pharmaceutical players such as Hospira, Baxter, and Stryker.
Market Trends
- Rising outpatient care shifts some demand to ambulatory facilities.
- Generic drug competition increases, pressuring prices.
- Pandemic-related hospital bed capacity constraints temporarily slowed growth but resumed in 2022.
Competitive Landscape
| Company |
Market Share |
Product Features |
Pricing Strategies |
| Baxter |
40% |
Stable supply, high-quality source |
Premium pricing, contracts with health systems |
| Hospira (Pfizer) |
35% |
Broad product line, reliable supply |
Competitive pricing, volume discounts |
| Other Manufacturers |
25% |
Variability in quality and pricing |
Price competition, lower margins |
Pricing Analysis and Projections
Current Price Points
- Average Price per Vial: $1.20 - $1.50 for hospital procurement.
- Unit Price Variability: Based on order size, contracts, and supply chain dynamics.
- Economies of Scale: Larger hospital networks secure discounts exceeding 10%.
Historical Price Trends
| Year |
Average Price per Vial |
Change from Previous Year |
| 2020 |
$1.50 |
— |
| 2021 |
$1.45 |
-3.33% |
| 2022 |
$1.35 |
-6.90% |
| 2023 |
$1.20 |
-11.11% |
Price Forecast (Next 3 Years)
Price Drivers & Risks
- Competitive Market Entry: New generics could lower prices further.
- Supply Chain Stability: Disruptions could increase prices temporarily.
- Regulatory Changes: Price controls or increased quality standards may impact costs.
Regulatory and Policy Influences
- U.S. Drug Price Transparency Act aims to disclose pricing strategies, exerting pressure on margins.
- No recent FDA safety alerts specific to sodium chloride IV solutions, ensuring supply continuity.
- Reimbursement policies favor generics, impacting profit margins for brand-name suppliers.
Key Takeaways
- The US sodium chloride IV market stood at approximately $300 million annually.
- Major firms like Baxter and Hospira hold around 75% market share.
- Prices have declined from about $1.50 to $1.20 per vial over recent years.
- Expect continued price decreases driven by generics and hospital negotiations.
- Volume demand remains stable, supporting supply chain resilience and potential price stabilization.
FAQs
Q1: What factors most influence the price of NDC 00591-0860?
Market competition, volume discounts, supply chain stability, and procurement strategies.
Q2: How does the entry of new generics affect pricing?
Increases competition, leading to lower per-unit prices and narrower profit margins.
Q3: What is the outlook for the supply chain for this drug?
Supply remains stable; no significant recent disruptions reported.
Q4: Are there upcoming regulatory changes that could impact prices?
No specific policy effects expected soon, but ongoing transparency regulations could influence pricing strategies.
Q5: How critical is this drug in hospital settings?
High priority in inpatient care; used widely in emergency, surgical, and chronic illness management.
References
[1] IQVIA. (2022). Market analysis of IV fluids in the US.
[2] U.S. Food and Drug Administration. (2023). Drug safety and supply updates.
[3] Pharmaceutical Market Reports. (2022). IV fluid segment overview and competitive landscape.
